Authors
1 Department of Medical Sciences, Nursing and Midwifery College, Islamic Azad University, Najafabad Branch, Isfahan, Iran
2 Faculty of Midwifery Group, Nursing and Midwifery College, Islamic Azad University, Najafabad Branch, Isfahan, Iran
Abstract
Background: Functional ovarian cysts include follicular, corpus luteum, and theca lutein cysts are the most common adnexal masses (about 50%) in women of reproductive age. Treatment with the combined monophasic oral contraceptives reduces functional ovarian cysts. Yaz (drospirenone/ethinyl estradiol) is a low-dose combined oral contraceptive pill containing 20 μg ethinyl estradiol and 3 mg drospirenone. In addition to contraceptive effects, Yaz has anti-mineralocorticoid and anti-adrenergic effects. Ovocept- low-dose LD is also a low-dose combined oral contraceptive drug containing 30 μg ethinyl estradiol and 3 mg norgestrol. Ovocept-LD has some side-effects such as weight gain, spotting, breast tenderness, nausea, and headache.
Materials and Methods: Being a clinical study, the present research was carried out on 42 patients with the simple ovarian cysts from 2010 to 2012. 84 Patients were assigned to A and B groups. Group A received Yaz once a day for a period of 28 days and group B received Ovocept-LD once a day for a period of 21 days. After treating by Yaz and Ovocept-LD, Cysts were evaluated by ultrasound. Results were analyzed by the SPSS software. A P < 0.05 was considered the significance threshold.
Results : Obtained results indicated that both Yaz and Ovocept-LD had an effect on the simple ovarian cysts. Statistical tests, however, has shown that the effect of Yaz has been significantly more than that of Ovocept-LD.
Conclusion: Given the faster and better recovery effect, and the lesser side effects of Yaz as compared to Ovocept-LD, it is recommended to use Yaz for the simple ovarian cysts.
Keywords
1. | Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2453-61. |
2. | Whiteside JL, Keup HL. Laparoscopic management of the ovarian mass: A practical approach. Clin Obstet Gynecol 2009;52:327-34. |
3. | Holt VL, Cushing-Haugen KL, Daling JR. Risk of functional ovarian cyst: Effects of smoking and marijuana use according to body mass index. Am J Epidemiol 2005;161:520-5. |
4. | Mavromatidis G, Sotiriadis A, Dinas K, Mamopoulos A, Rousso D. Large luteinized follicular cyst of pregnancy. Ultrasound Obstet Gynecol 2010;36:517-20. |
5. | Engiz O, Berberoglu M, Siklar Z, Bilir P, Ocal G. Treatment of autonomous ovarian follicular cyst with long-term anastrozole therapy. Indian J Pediatr 2009;76:950-1. |
6. | Monnoyer S, Guyonnet J, Toutain PL. A preclinical pharmacokinetic/pharmacodynamic approach to determine a dose of GnRH, for treatment of ovarian follicular cyst in cattle. J Vet Pharmacol Ther 2004;27:527-35. |
7. | Swire MN, Castro-Aragon I, Levine D. Various sonographic appearances of the hemorrhagic corpus luteum cyst. Ultrasound Q 2004;20:45-58. |
8. | Huang PH, Tsai KB, Tsai EM, Su JH. Hemorrhagic corpus luteum cyst torsion in term pregnancy: A case report. Kaohsiung J Med Sci 2003;19:75-8. |
9. | Atri M. Ectopic pregnancy versus corpus luteum cyst revisited: Best Doppler predictors. J Ultrasound Med 2003;22:1181-4. |
10. | Nguyen KT, Reid RL, Sauerbrei E. Antenatal sonographic detection of a fetal theca lutein cyst: A clue to maternal diabetes mellitus. J Ultrasound Med 1986;5:665-7. |
11. | Lanes SF, Birmann B, Walker AM, Singer S. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992;166:956-61. |
12. | Feng Y, Johansson J, Shao R, Mannerås-Holm L, Billig H, Stener-Victorin E. Electrical and manual acupuncture stimulation affect oestrous cyclicity and neuroendocrine function in an 5α-dihydrotestosterone-induced rat polycystic ovary syndrome model. Exp Physiol 2012;97:651-62. |
13. | Crave JC, Fimbel S, Lejeune H, Cugnardey N, Déchaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995;80:2057-62. |
14. | Rebelo AC, Zuttin RS, Verlengia R, Cesar Mde C, de Sá MF, da Silva E. Effect of low-dose combined oral contraceptive on aerobic capacity and anaerobic threshold level in active and sedentary young women. Contraception 2010;81:309-15. |
15. | Tanne JH. Bayer to spend $20m to correct misleading advertising for oral contraceptive Yaz. BMJ 2009;338:b674. |
16. | Kebapcilar L, Baghaei F, Holm G. Coagulation and fibrinolytic disturbances in woman with polycystic ovary syndrome. J Clin Endocrinol Metab 1968;96:2011. |
17. | Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception 2010;82:139-46. |
18. | Alessandro D, Genazzani AP. Ovarian cystic formation during depot formulation of GnRH-A Therapy and effect of pretreatment with oral contraceptive pills on ovarian cysts. Fertil Steril 2008;7:109-13. |
19. | Johnson N, Reilly S. The pill for ovarian cysts. Biol Med 2010;12:25-8. |
20. | Palep-Singh M, Mook K, Barth J, Balen A. An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care 2004;30:163-5. |
21. | Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: A clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004;89:2817-23. |